prikaz prve stranice dokumenta Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers
  Preuzmi
PDF 654.15 KB
Znanstveni rad - Izvorni znanstveni rad
Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers
Neurology and Therapy, 12 (2022), 1; 25-37. https://doi.org/10.1007/s40120-022-00422-z
Habek, Mario; Drulović, Jelena; Brecl Jakob, Gregor; Barbov, Ivan; Radulovic, Ljiljana; Rajda, Cecilia; Rejdak, Konrad; Turčáni, Peter

Citirajte ovaj rad

Habek, M., Drulović, J., Brecl Jakob, G., Barbov, I., Radulovic, Lj., Rajda, C. ... Turčáni, P. (2022). Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers. Neurology and Therapy, 12. (1), 25-37. doi: 10.1007/s40120-022-00422-z

Habek, Mario, et al. "Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers." Neurology and Therapy, vol. 12, br. 1, 2022, str. 25-37. https://doi.org/10.1007/s40120-022-00422-z

Habek, Mario, Jelena Drulović, Gregor Brecl Jakob, Ivan Barbov, Ljiljana Radulovic, Cecilia Rajda, Konrad Rejdak i Peter Turčáni. "Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers." Neurology and Therapy 12, br. 1 (2022): 25-37. https://doi.org/10.1007/s40120-022-00422-z

Habek, M., et al. (2022) 'Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers', Neurology and Therapy, 12(1), str. 25-37. doi: 10.1007/s40120-022-00422-z

Habek M, Drulović J, Brecl Jakob G, Barbov I, Radulovic Lj, Rajda C, i sur.. Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers. Neurology and Therapy [Internet]. 17.11.2022. [pristupljeno 17.10.2024.];12(1):25-37. doi: 10.1007/s40120-022-00422-z

M. Habek, et al., "Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers", Neurology and Therapy, vol. 12, br. 1, str. 25-37, Studeni 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:261927. [Citirano: 17.10.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:261927
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers
AutorMario Habek
AutorJelena Drulović
AutorGregor Brecl Jakob
AutorIvan Barbov
AutorLjiljana Radulovic
AutorCecilia Rajda
AutorKonrad Rejdak
AutorPeter Turčáni
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA NEUROLOGIJU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Neurologija
Sažetak (engleski)
Based on the results of the pivotal CLARITY study, cladribine tablets were approved for use in the European Union in 2017 as a high-efficacy therapy for highly active relapsing-remitting multiple sclerosis (MS). Cladribine tablets are used as an induction therapy: half of the total dose is given in year 1 and the other half in year 2. In the CLARITY Extension trials, repeating the dose routinely in years 3 and 4, was not associated with significantly improved disease control. However, there is very limited evidence on how to manage people with MS (pwMS) beyond year 4, which is increasingly important because more and more patients are now ≥ 4 years after cladribine treatment. Overall, postapproval data show that treatment with two cladribine cycles effectively controls disease activity in the long term. However, there is general agreement that some pwMS with suboptimal response could benefit from retreatment. This study reviews the practical aspects of using cladribine tablets, summarizes the evidence from clinical trials and real-world studies on the safety and efficacy of cladribine, and proposes a treatment algorithm developed by expert consensus for pwMS previously treated with cladribine. In brief, we propose that additional courses of cladribine tablets should be considered in patients with minimal (no relapses, 1-2 new lesions) or moderate (1 relapse, 3-4 new lesions) disease activity, while significant disease activity (> 1 relapse, > 3 new lesions) or progression should warrant a switch to another high-efficacy treatment (HET). More evidence is needed to improve the treatment guidelines for pwMS who previously received cladribine.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaNeurology and Therapy
Brojčani podacivol. 12, br. 1, str. 25-37
p-ISSN2193-8253
e-ISSN2193-6536
DOIhttps://doi.org/10.1007/s40120-022-00422-z
URN:NBNurn:nbn:hr:105:261927
Datum objave publikacije2022-11-17
URL dokumentahttps://link.springer.com/10.1007/s40120-022-00422-z
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno 4.0 međunarodna (CC BY-NC 4.0)
Datum i vrijeme pohrane2023-07-11 11:55:26